Verastem Oncology to Present Updated KRAS G12D Inhibitor Data in June 23 Call

Event summary

  • Verastem Oncology will host an investor call on June 23, 2026, to report updated data and progress on its VS-7375 oral KRAS G12D (ON/OFF) inhibitor TARGET-D clinical program.
  • The company will present preliminary Phase 1/2 TARGET-D 101 trial data, including safety, tolerability, and pharmacokinetic findings across pancreatic, colorectal, and non-small lung cancers.
  • VS-7375 has received Fast Track Designation from the FDA for pancreatic cancer and non-small cell lung cancer indications.
  • Verastem licensed VS-7375 from GenFleet Therapeutics in January 2025, with development and commercialization rights outside China.

The big picture

Verastem Oncology's focus on KRAS G12D inhibition aligns with the broader industry trend of targeting specific genetic mutations in oncology. The Fast Track Designation from the FDA underscores the unmet medical need in pancreatic and lung cancers, positioning VS-7375 as a potential best-in-class therapy. The strategic collaboration with GenFleet Therapeutics provides Verastem with exclusive rights outside China, enhancing its global commercialization prospects.

What we're watching

Clinical Efficacy
How the updated Phase 1/2 data will demonstrate the safety and efficacy of VS-7375 as a monotherapy and in combination therapies.
Regulatory Pathway
Whether the Fast Track Designation will accelerate the approval process for VS-7375 in key indications.
Commercial Strategy
The pace at which Verastem can advance VS-7375 through Phase 2 registration-directed trials and potential market entry.